DAWN (STOCKS)
Day One Biopharmaceuticals, Inc. Common Stock
$11.230000
-0.190000 (-1.66%)
Prev close: $11.420000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Jeremy Bender
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,187.05M
- Employees
- 181
- P/E (TTM)
- -7.69
- P/B (TTM)
- 2.60
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
10
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.19 | $-0.30 | +0.1086 | +36.37% |
|
Jun 2025 (Q2)
|
$-0.29 | $-0.36 | +0.0740 | +20.33% |
|
Mar 2025 (Q1)
|
$-0.35 | $-0.45 | +0.1014 | +22.46% |
|
Dec 2024 (Q4)
|
$-0.64 | $-0.37 | -0.2708 | -73.35% |
Financial Statements
| Revenues | $133.67M |
| Benefits Costs and Expenses | $0.00 |
| Costs And Expenses | $299.30M |
| Nonoperating Income/Loss | $20.34M |
| Operating Expenses | $299.30M |
| Research and Development | $169.01M |
| Other Operating Expenses | $130.29M |
| Operating Income/Loss | -$165.62M |
| Income/Loss From Continuing Operations After Tax | -$33.00M |
| Income/Loss From Continuing Operations Before Tax | $2.69M |
| Income Tax Expense/Benefit | $6.47M |
| Net Income/Loss | -$72.79M |
| Net Income/Loss Attributable To Noncontrolling Interest | $145.28M |
| Net Income/Loss Attributable To Parent | -$151.76M |
| Net Income/Loss Available To Common Stockholders, Basic | -$151.76M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.52 |
| Diluted Earnings Per Share | -$1.52 |
| Basic Average Shares | 106,125,346 |
| Diluted Average Shares | 106,125,346 |
| Assets | $513.78M |
| Current Assets | $489.97M |
| Accounts Receivable | $16.70M |
| Inventory | $7.06M |
| Other Current Assets | $466.21M |
| Noncurrent Assets | $23.81M |
| Fixed Assets | $2.23M |
| Other Non-current Assets | $21.58M |
| Liabilities | $62.91M |
| Current Liabilities | $56.47M |
| Accounts Payable | $5.78M |
| Other Current Liabilities | $50.69M |
| Noncurrent Liabilities | $6.45M |
| Equity | $450.87M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $450.87M |
| Liabilities And Equity | $513.78M |
| Net Cash Flow From Operating Activities | -$119.62M |
| Net Cash Flow From Operating Activities, Continuing | -$119.62M |
| Net Cash Flow From Investing Activities | -$262.47M |
| Net Cash Flow From Investing Activities, Continuing | -$262.47M |
| Net Cash Flow From Financing Activities | $2.60M |
| Net Cash Flow From Financing Activities, Continuing | $2.60M |
| Net Cash Flow | -$379.49M |
| Net Cash Flow, Continuing | -$379.49M |
| Comprehensive Income/Loss | -$151.51M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$151.68M |
| Other Comprehensive Income/Loss | -$85.19M |